Opthea Completes Successful FDA and EMA Meetings for Phase 3
Filed with ASX · · 3 pages · English
Earlier from Opthea
- Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)
- S&P DJI Announces June 2020 Quarterly Rebalance
- Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
- Opthea Completes Patient Dosing in Phase 2a DME Trial
- Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME
Later from Opthea
- Opthea Announces Plans for Potential US listing and IPO
- Opthea Full Year Financial Report 2020
- Opthea Files Registration Statement for Proposed US IPO
- Results of Meeting
- Opthea Launches Proposed US Initial Public Offering
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea